Company Profile
Dermapharm - Pharmaceutical Excellence
“Made in Europe”
Dermapharm is an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products. Founded in 1991, the Company is based in Grünwald near Munich. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Germany, the rest of Europe and the United States.
In the "Branded pharmaceuticals" segment, Dermapharm has more than 1,300 marketing authorisations with around 400 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals is tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany. The Company's integrated business model extends from in-house product development and production through quality management and logistics to the distribution of branded pharmaceuticals by a trained pharmaceutical sales force.
Dermapharm bundles food supplements, herbal pharmaceuticals, cosmetics, medical devices, herbal extracts and medicinal cannabis in its "Other healthcare products" segment. In this segment, Dermapharm can tap the expertise of the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries, and Arkopharma, the market leader for herbal medicines and food supplements in France.
Dermapharm also operates the "Parallel import business" segment under the axicorp brand. axicorp imports originator pharmaceuticals from other EU Member States and resells them to pharmaceuticals wholesalers and pharmacies in Germany. This enables axicorp to benefit from the different pricing structures in the individual EU member states. Based on revenue, axicorp is currently one of the top six parallel import companies in Germany.
With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, the Group is continuously optimising its business activities and seeks external growth opportunities in addition to organic growth.
WILHELM BEIER
Wilhelm Beier was born in Eicherscheid (Bad Münstereifel), Germany, on April 21, 1956. Starting his career in 1981, he held various positions in the pharmaceuticals industry, including a managing director of the German subsidiaries of an international pharmaceuticals manufacturer. After founding Dermapharm in 1991, Mr. Beier served as Chief Executive Officer of Dermapharm AG.
In 2017, he was appointed chairman of the supervisory board of Dermapharm.
Mr. Beier and his family hold the majority of the company's shares via Themis Beteiligungs AG.
DR. ERWIN KERN
Dr Erwin Kern was born on July 6, 1960 in Karlsruhe, Germany. In 1986, Dr. Kern completed his studies in business administration at the Ludwig Maximilian University in Munich. In 1989, he received his doctorate in economics from the University of Paderborn. Dr. Kern began his professional career in 1986 as Managing Director of HBK-Handel und Beteiligungen Kern GmbH & Co. KG. From 1991 onwards, he was a member of the management of Kies und Beton Baden-Baden GmbH & Co. Holding KG and Kies und Beton AG Baden-Baden. In 2007, Dr. Kern took over the chairmanship of the management of these companies, which he still holds today. Since 2003, he has been President of the Federal Association of the German Ready-Mixed Concrete Industry (BTB). (BTB) since 2003 and was Chairman from 2008 to 2011 and Vice Chairman from 2011 to 2013 of Construction Products Europe (CPE) (Association of European Construction Materials Manufacturers).
Dr Kern was appointed as a member of the Supervisory Board of Dermapharm Holding SE in 2017. In addition to his position at Dermapharm, Dr Kern was and is active in various companies and associations in the stone and earth industry that are not listed on the stock exchange.
LOTHAR LANZ
Lothar Lanz was born on October 1, 1948 in Bihlafingen, Germany. From 1969 to 1974, Mr. Lanz studied business administration at the universities of Stuttgart and Berlin and graduated with a degree in business administration. Mr. Lanz began his professional career as an audit assistant for an auditor and tax consultant in Berlin. In 1977, Mr. Lanz joined Bayerische Hypotheken- und Wechselbank AG, where he served as branch manager from 1983 to 1990. In 1991, Mr. Lanz became a member of the Board of Management of H.S.B. HYPO Service-Bank AG, Munich. In 1996, he moved to Nassauische Sparkasse, Wiesbaden, where he also became a member of the Board of Management. In the same year, Mr. Lanz moved to the then ProSieben Media AG (now ProSiebenSat.1 Media AG) as Chief Financial Officer, a post he held until 2008. From 2009 to 2014, Mr. Lanz was a member of the Executive Board of Axel Springer AG (now Axel Springer SE), where he served as Chief Financial and Operating Officer.
Mr. Lanz was appointed as a member of the Supervisory Board of Dermapharm Holding SE in 2018. In addition, he is currently Chairman of the Supervisory Board of Home 24 SE, a member of the Supervisory Board of TAG Immobilien AG and the unlisted Bauwert AG as well as Chairman of the Board of Directors of the unlisted SMG Swiss Marketplace Group AG. Until 2019, he was also a member of the Supervisory Board of Axel Springer SE and Chairman of the Supervisory Board of Zalando SE.
Corporate Governance
Corporate Governance Documents
-
-
Other documents
Articles of Association
ARTICLES OF ASSOCIATION DERMAPHARM HOLDING SE 2023
ARTICLES OF ASSOCIATION DERMAPHARM HOLDING SE 2021
ARTICLES OF ASSOCIATION DERMAPHARM HOLDING SE 2020
Audit CommitteeSPECIAL PROVISIONS FOR THE PERFORMANCE OF THE DUTIES OF AN AUDIT COMMITTEE 2022
Rules of procedureRULES OF PROCEDURE OF THE SUPERVISORY BOARD OF DERMAPHARM HOLDING SE 2022
RULES OF PROCEDURE OF THE SUPERVISORY BOARD OF DERMAPHARM HOLDING SE 2018
Remuneration system -
In-house product development
The Dermapharm Group develops pharmaceuticals and other healthcare products in its core therapeutic areas at four corporate locations, where experienced experts conduct development and authorisation activities – including designing and funding clinical trials. Once authorisation is granted, newly developed products are generally put into production in-house. In total, the Group manufactures about 90% of the pharmaceutical product portfolio itself.
The focal points of the development work are:
Expanding the portfolio of off-patent branded pharmaceuticals in dermatology
Further developing allergy therapy product range
Developing science-based food supplements
Developing new phytoextracts
Further developing the range of medical devices
Internationalisation
The Dermapharm Group has been operating in Austria, Switzerland, Croatia, Poland and Ukraine for many years now. In order to further expand its business with branded pharmaceuticals and other healthcare products, the Group has formed subsidiaries in Italy and Spain. Country-specific portfolios are formed/developed based in each case on a detailed analysis of market conditions, with compounds developed and manufactured by the Group in particular receiving marketing authorisation. This enables the Group to gradually enlarge its portfolio and the respective sales and distribution structures as it expands into new markets. For instance, the Dermapharm Group is expanding into other countries in Europe, Asia and the Americas with its CE-certified and internationally patented medical devices bite away® and Herpotherm®.
Another key aspect of the Group's internationalisation efforts is the acquisition of companies with international operations. With the acquisition of Euromed, Dermapharm is represented with herbal extracts in Spain. Allergopharma and Cernelle also contribute to further internationalisation. Most recently, the Dermapharm Group gained market access to Western and Southern Europe with the acquisition of Arkopharma.
M&A activities
Acquiring individual products, portfolios and companies has always been part of Dermapharm's business strategy and a key success factor for its continued growth. Since its formation in 1991, the Group has steadily expanded its product offering through successful acquisitions in Germany and abroad. This includes, for instance, the acquisition of attractive patented medical devices and pharmaceutical manufacturers, which complement the Group's portfolio ideally and expand its offering in growth markets. Another aim when making these types of acquisitions is to further increase the potential of the newly acquired companies by optimising processes and incorporating the companies in the Group's production and logistics structures. The Dermapharm Group continually reviews specific growth opportunities and pursues promising acquisition options that fit its strategic alignment.
